Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 8/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 8/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2562807 | 0.77 | KDM4E (0.34) | HIF1AEPAS1USP2PABPC1KDM4E | |
| SCHEMBL15052201 | 0.77 | HIF1A (0.53) | HIF1AEPAS1HTR2AHTT | |
| SCHEMBL2564066 | 0.76 | ALDH1A1 (0.38) | HIF1AEPAS1USP2PABPC1CXCR4 | |
| SCHEMBL15052336 | 0.74 | HIF1A (0.53) | HIF1AEPAS1HTR2AHTT | |
| SCHEMBL15760106 | 0.71 | KCNH2 (0.50) | KCNH2 | |
| SCHEMBL15052753 | 0.71 | HIF1A (0.55) | HIF1AEPAS1HTR2AHTT | |
| SCHEMBL30814161 | 0.71 | HIF1A (0.48) | HIF1AEPAS1KCNH2 | |
| SCHEMBL25044370 | 0.64 | KDM1A (0.55) | USP2PABPC1KDM4EMEN1KMT2A | |
| SCHEMBL26021280 | 0.64 | CXCR4 (0.51) | USP2PABPC1CXCR4KDM4EKMT2A | |
| SCHEMBL22146132 | 0.61 | KCNH2 (0.43) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9062072-B2 | Inhibitors of HIF and angiogenesis | EMORY UNIVERSITY (US) | 2015-06-23 | — | — | US | disclosed |
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2011133659-A2 | INHIBITORS OF HIF AND ANGIOGENESIS | EMORY UNIVERSITY (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116275-A1 | INHIBITORS OF HIF AND ANGIOGENESIS | HIF1AN, HIF1A, EGLN2 | HIF1A 2/4885EPAS1 16/4885HTR2A 2962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.